Overview

• The clinical trial, conducted at S:t Eriks Eye Hospital in Stockholm, is recruiting patients with primary open-angle glaucoma and pseudoexfoliation glaucoma.
• Preclinical studies demonstrated that vitamins B6, B9, B12, and choline slowed or stopped optic nerve damage in animal models of glaucoma, even without lowering intraocular pressure.
• The research identified dysfunctional one-carbon metabolism in the retina as a key factor impairing vitamin utilization and contributing to glaucomatous neurodegeneration.
• Homocysteine, previously suspected as a driver of glaucoma, was found to be a bystander biomarker rather than a causative factor in disease progression.
• If successful, this therapy could complement traditional pressure-lowering treatments, offering a novel approach to preserving vision in glaucoma patients.